

AMENDMENT TO THE CLAIMS

Claim 1 (Withdrawn): A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can selectively kill *Fusobacterium varium* cells.

Claim 2 (Withdrawn): A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can neutralize the toxin produced by *Fusobacterium varium* cells.

Claim 3 (Withdrawn): A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can inhibit the adhesion of *Fusobacterium varium* cells to the intestinal mucosa.

Claim 4 (Withdrawn): A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can inhibit the invasion of *Fusobacterium varium* cells into the intestinal mucosa.

Claim 5 (Withdrawn): A vaccine for preventing ulcerative colitis from infection with *Fusobacterium varium* comprising a drug as set forth in claim 1.

Claim 6 (Withdrawn): A vaccine for preventing ulcerative colitis from infection with *Fusobacterium varium* comprising a drug as set forth in claim 2.

Claim 7 (Withdrawn): A vaccine for preventing ulcerative colitis from infection with *Fusobacterium varium* comprising a drug as set forth in claim 3.

Claim 8 (Withdrawn): A vaccine for preventing ulcerative colitis from infection with *Fusobacterium varium* comprising a drug as set forth in claim 4.

Claim 9 (Withdrawn): A method for screening a drug for selectively killing *Fusobacterium varium* cells comprising the step of administering a drug to be examined to an experimental model of *Fusobacterium varium*-infection to thus select a drug, which can selectively kill the bacterium.

Claim 10 (Withdrawn): A method for screening a therapeutic agent for ulcerative colitis comprising the step of administering a candidate drug which selectively kills the bacterium in a patient with ulcerative colitis and positive to *Fusobacterium varium* to thus select a drug capable of improving the symptoms of the patients suffering from the disease.

Claim 11 (Withdrawn): An animal as a model of ulcerative colitis obtained by administering a toxin produced by *Fusobacterium varium* to an animal.

Claim 12 (Withdrawn): The animal model of ulcerative colitis as set forth in claim 11, wherein the toxin is butyric acid.

Claim 13 (Withdrawn): An animal as a model for ulcerative colitis comprising living *Fusobacterium varium* cells adhered to the mucosa.

Claim 14 (Canceled)

Claim 15 (Withdrawn): An agent for making a diagnosis of ulcerative colitis comprising an antibody against *Fusobacterium varium*, which has the highest detection sensitivity and the highest specificity.

Claim 16 (Currently Amended): A method for making a diagnosis of ulcerative colitis caused by *Fusobacterium varium* in a patient, which comprises:

- (a) obtaining sera from said patient;
- (b) detecting an antibody ~~specific~~ for *Fusobacterium varium* in said sera; and
- (c) correlating the presence of an antibody ~~specific~~ for *Fusobacterium varium* in said sera with ulcerative colitis.

Claim 17 (Previously Presented): The method of Claim 16, wherein said antibody is detected using western blotting method.

Claim 18 (Previously Presented): The method of Claim 16, wherein said antibody is detected using enzyme-linked immunosorbent assay (ELISA).

Claim 19 (New): The method of Claim 16, wherein said method for making a diagnosis of ulcerative colitis is a differential diagnosis between ulcerative colitis and inflammatory bowel disease.

SUPPORT FOR THE AMENDMENTS

Claim 16 has been amended.

Claim 19 has been added.

The amendment of Claim 16 is supported by original Claim 14 and in the description on page 5, lines 7 to 11, and page 9, lines 2 to 6, of the specification. New Claim 19 is supported by the specification at page 7, lines 1-4.

No new matter is believed to have been entered by the present amendment.